Transcript Presentation Title Here in Boldface 36 Point Type

SAFC Press Briefing
Informex 2012
Gilles Cottier
President of SAFC
February 16, 2012
© 2011 SAFC
Business confidential
SAFC Results for 2011
• $728 Million in Sales
• • 9% Organic Growth
• • 2011 performance driven by our
industrial media and Hitech sales,
which both grew double digits
2
© 2011 SAFC
Business confidential
2012 Highlights
• Grow SAFC business in high
single-digit by leveraging customer
focus, unique manufacturing
capabilities and adjacent services
• SAFC Hitech plant in Taiwan
on-line in Q1 2012
3
© 2011 SAFC
Business confidential
BioReliance Overview
2010 Revenue by Segment
Biologics
Toxicology
Animal Health Services
Global biopharmaceutical services
organization
– Biologics Testing: global market leader
for safety testing and support services for
manufacturers of biologic therapeutics
– Specialized Toxicology Studies: global
market leader for genetic toxicology testing;
leader in transgenic model studies for
oncogenicity
– Animal Health Services: broad spectrum
of laboratory animal diagnostic and
analytical services for health monitoring
and disease outbreak
2010 Revenue: $110M
Global Facilities
Glasgow, Scotland
Stirling, Scotland
Tokyo, Japan
Rockville, USA
Bangalore, India
Total Employees: ~650
BioReliance currently performs testing for ~75% of the top Pharma companies and
~90% of the top Biotech companies in the world.
© 2011 SAFC
4
Business confidential
BioReliance Strategic Rationale and Transaction
Benefits
•Strategic Context
– Combination creates one of the broadest
product and services offerings for the
development and manufacturing of biological
drugs
– Benefits biopharmaceutical customers with a
broad portfolio of product solutions and
services
– Provides platform from which to expand
across laboratory and biological services
Financial Impact
– Purchase price approximately $350 in cash
– Expected to be accretive to growth rate and
earnings in 2012
– Opportunity to drive incremental revenue
growth and returns over time through crossselling, geographic expansion and expansion
of technology platform
5
© 2011 SAFC
Business confidential
Complementary Biologic Development &
Manufacturing Overview
Upstream Bioprocessing
Research
Cell Line
Downstream Bioprocessing
Production Cell
Line (“Cell
Bioreactor
Bank”)
Cloning, cell
Media development,
selection &
upstream process
expansion
optimization (“scale up”)
Raw Material Testing
Unprocessed
Bulk Product
Process
Chromatography
Purified Bulk
Drug
Substance
Final Drug
Product
Formulation
development,
stability testing, fill
& finish
Lot Release & Downstream Process Testing
Raw Material Manufacturing & Supply
Expression System and
Cell Line Development
Contract Biologic Manufacturing
Upstream Process Development
Legend:
BioReliance
Sigma-Aldrich/SAFC
6
© 2011 SAFC
Business confidential